Azithromycin versus doxycycline for urogenital chlamydia trachomatis infection

New England Journal of Medicine

Volumn 373, Issue 26, 2015, Pages 2512-2521

  Geisler, William M ^a   Uniyal, Apurva ^b   Lee, Jeannette Y ^e   Lensing, Shelly Y ^e   Johnson, Shacondra ^f   Perry, Raymond C W ^d   Kadrnka, Carmel M ^d   Kerndt, Peter R ^b,c  

^a University of Alabama at Birmingham   (United States)

^b Department of Preventive Medicine ^*  (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; OUTER MEMBRANE PROTEIN A; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; CHLAMYDIA TRACHOMATIS; CHLAMYDIAL URETHRITIS; CHLAMYDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; MEN WHO HAVE SEX WITH MEN AND WOMEN; NUCLEIC ACID AMPLIFICATION; PELVIC INFLAMMATORY DISEASE; PELVIC PAIN; PENIS DISCHARGE; PENIS DISEASE; PRIORITY JOURNAL; PRISON; SCROTAL PAIN; SEXUAL BEHAVIOR; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VAGINA BLEEDING; VAGINA DISCHARGE; WOMEN WHO HAVE SEX WITH WOMEN; CHLAMYDIA INFECTIONS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DIRECTLY OBSERVED THERAPY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEXUALITY; URINE; YOUNG ADULT;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CONFIDENCE INTERVALS; DIRECTLY OBSERVED THERAPY; DOXYCYCLINE; FEMALE; HUMANS; MALE; PRISONS; SEXUAL PARTNERS; TREATMENT FAILURE; URINE; YOUNG ADULT;

EID: 84952056755     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1502599     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2013. Atlanta: Department of Health and Human Services, 2014.
2. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections - 2008 (http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en).
3. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12): 1-110.
4. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29: 497-502.
5. Bachmann LH, Stephens J, Richey CM, Hook EW III. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis 1999; 26: 272-8.
6. Khosropour CM, Manhart LE, Colombara DV, et al. Suboptimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study. Sex Transm Infect 2014; 90: 3-7.
7. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58: 686-99.
8. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis 2010; 201: Suppl 2: S88-S95.
9. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens - a randomized clinical trial. Clin Infect Dis 2011; 52: 163-70.
10. Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis 2013; 56: 934-42.
11. Takahashi S, Matsukawa M, Kurimura Y, et al. Clinical efficacy of azithromycin for male nongonococcal urethritis. J Infect Chemother 2008; 14: 409-12.
12. Geisler WM, Pascual ML, Mathew J, et al. Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women. Antimicrob Agents Chemother 2014; 58: 4014-9.
13. Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010; 201: 42-51.
14. Mertz KJ, Voigt RA, Hutchins K, et al. Findings from STD screening of adolescents and adults entering correctional facilities. Sex Transm Dis 2002; 29: 834-9.
15. Bauer HM, Chartier M, Kessell E, et al. Chlamydia screening of youth and young adults in non-clinical settings throughout California. Sex Transm Dis 2004; 31: 409-14.
16. Robertson AA, Thomas CB, St Lawrence JS, Pack R. Predictors of infection with chlamydia or gonorrhea in incarcerated adolescents. Sex Transm Dis 2005; 32: 115-22.
17. Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health 2011; 8: 69-73.
18. Morré SA, Sillekens PT, Jacobs MV, et al. Monitoring of Chlamydia trachomatis infections after antibiotic treatment using RNA detection by nucleic acid sequence based amplification. Mol Pathol 1998; 51: 149-54.
19. Workowski KA, Lampe MF, Wong KG, Watts MB, Stamm WE. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy: evidence against persistent infection. JAMA 1993; 270: 2071-5.
20. Gaydos CA, Crotchfelt KA, Howell MR, Kralian S, Hauptman P, Quinn TC. Molecular amplification assays to detect chlamydial infections in urine specimens from high school female students and to monitor the persistence of chlamydial DNA after therapy. J Infect Dis 1998; 177: 417-24.
21. Kapil R, Press CG, Hwang ML, Brown L, Geisler WM. Investigating the epidemiology of repeat Chlamydia trachomatis detection after treatment by using C. trachomatis OmpA genotyping. J Clin Microbiol 2015; 53: 546-9.
22. International Conference on Harmonisation E9 Expert Working Group. ICH Harmonised Tripartite Guideline: statistical principles for clinical trials. Stat Med 1999; 18: 1905-42.
23. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012; 308: 2594-604.
24. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000; 181: 1421-7.
25. Jones RB, Van der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 1990; 162: 1309-15.
26. Worm AM, Osterlind A. Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis. Genitourin Med 1995; 71: 244-6.
27. Krohn K. Gynaecological tissue levels of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10: 864-8.
28. Reveneau N, Crane DD, Fischer E, Caldwell HD. Bactericidal activity of firstchoice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. Antimicrob Agents Chemother 2005; 49: 1787-93.
29. Dean D, Suchland RJ, Stamm WE. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J Infect Dis 2000; 182: 909-16.
30. Recommendations for the laboratorybased detection of Chlamydia trachomatis and Neisseria gonorrhoeae - 2014. MMWR Recomm Rep 2014; 63(RR-02): 1-19.
31. Chernesky M, Jang D, Gilchrist J, et al. Head-to-head comparison of second-generation nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae on urine samples from female subjects and self-collected vaginal swabs. J Clin Microbiol 2014; 52: 2305-10.